NCT07443202
Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
Enrolling by Invitation
PHASE2Ages 18+InterventionalTreatmentTarsus Pharmaceuticals, Inc.
~155 participants
Updated 2026-03-02 on ClinicalTrials.gov
What's tested:lotilanerVehicle
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Treatment Emergent Adverse Events
Measured over Week 16
Conditions
Where it's being run
2 sites across 2 statesTexas1
Virginia1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
18 years of age or older at the time of consent.
Has moderate to severe ocular rosacea
Use of acceptable methods of contraception
Are willing to sign the informed consent form and is deemed capable of complying with the requirements of the study protocol
Exclusion
Patient taking a topical or other therapy which may affect the patients rosacea
Actively managed glaucoma or active ocular infection or ocular systemic disease
Have hypersensitivity to lotilaner or any of the formulation components
Are currently enrolled in an investigational drug or device study
Are currently pregnant or lactating or planning to become pregnant during the study
What this trial measures
- Incidence of Treatment Emergent Adverse EventsWeek 16
Number of patients with treatment related emergent adverse events (TEAEs)